Market Overview

Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio's Drug Acquisition and Development Capabilities


Rallybio LLC, a development-stage biotechnology company, today
announced that it has further expanded its drug acquisition and
development capabilities with the addition of Laura Ekas, PhD and Eric
Watsky, MD to the Rallybio team. Dr. Ekas and Dr. Watsky now join
Rallybio's co-founders and other veteran industry executives in
advancing Rallybio's mission to identify and accelerate the
development of transformative breakthrough therapies for patients with
severe and rare disorders.

Rallybio was co-founded in January 2018 by Martin Mackay, PhD,
Stephen Uden, MD, and Jeffrey Fryer, CPA, recognized leaders from the
biopharma industry. In April, the company announced that it had secured
$37.0 million in Series A funding. Rallybio's focus is on
antibodies, small molecules and engineered proteins that have strong
biological rationales for addressing specific disease mechanisms.

Laura Ekas, PhD

Dr. Ekas brings Rallybio more than 10 years of experience
in the biopharma industry, including in-depth scientific and clinical
analysis of therapeutic candidates, assessments of global drug markets,
and corporate operations. Most recently, she served as Director of
Global Pricing and Reimbursement for Alexion Pharmaceuticals, where she
led cross-functional teams to secure funded access to rare disease drugs
in countries across North America, Latin America, Europe and
Australasia. Before that, she was Chief of Staff to Alexion's CEO and
CFO, with responsibilities that included corporate planning, and the
development and implementation of cross-functional corporate strategies,
policies, and initiatives. Dr. Ekas originally joined Alexion in the
investor relations function. Prior to Alexion, Dr. Ekas was Vice
President, Senior Equity Research Analyst at Canaccord Genuity, where
she conducted both medical/scientific and commercial due diligence on
more than 50 biotech companies working across multiple therapeutic
areas. Dr. Ekas received her PhD in Pharmacology and Signal Transduction
from the New York University School of Medicine.

"Laura's strengths include the deep scientific and clinical analysis of
development candidates across the spectrum from pre-clinical through
approved medicines," said Dr. Mackay. "She is an important addition to
our team as we review a large number of potential assets from sources
around the globe."

"Important work in basic science and pre-clinical development is taking
place across some of the most severe and previously unaddressed rare
diseases. I am thrilled to join the Rallybio team, which has the
passion and know-how to bring life-transforming treatments to patients
suffering from rare diseases," said Dr. Ekas.

Eric Watsky, MD

Dr. Watsky joins Rallybio with 22 years of experience in
pharmaceutical research and development, as well as additional
experience in patient care and clinical research in academia and at the
National Institutes of Health. Most recently, Dr. Watsky served as Vice
President, Global Development Team Leader for Alexion Pharmaceuticals,
where he led clinical programs for first-in-class therapies for multiple
orphan and ultra-orphan diseases. Prior to Alexion, Dr. Watsky held
positions of increasing responsibility at Pfizer, rising to the role of
Executive Director in the Specialty Care Business Unit focused on rare
disease indications. His work at Pfizer included both exploratory and
late-stage clinical development of more than 30 approved drugs and drug
candidates in support of both clinical research and commercialization.
Prior to Pfizer, Dr. Watsky was a Senior Staff Research Fellow at the
National Institute of Mental Health. Dr. Watsky received his MD from
Boston University and has taught at the medical schools of Harvard,
where he was Chief Resident in Psychopharmacology, and George Washington

"Eric is a very strong and broadly experienced drug developer who has
worked on the clinical development programs for several medicines,
including orphan drugs, from first-in-human studies through regulatory
approval and into the marketplace," said Dr. Mackay. "We will benefit
greatly from his special expertise in designing clinical studies and
working with regulators in rare disease settings where there are
essentially no established regulatory pathways."

"The assets we are reviewing have strong and clear clinical potential to
treat patients who currently suffer from a lack of effective treatment
options," said Dr. Watsky. "I am happy to be joining the Rallybio
team and look forward to advancing the most promising of these
candidates into clinical development."

About Rallybio

Rallybio was established to identify and accelerate the
development of transformative breakthrough therapies for patients with
severe and rare disorders. The founders of the company – Martin Mackay,
PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders
from the biopharma industry with a wide breadth of research,
development, and financial experience. Rallybio has earned
the support of highly-respected investors in the bioscience sector and
announced in April 2018 that it had secured $37.0 million in a Series A
funding led by 5AM Ventures, Canaan Partners, and New Leaf Venture
Partners, with additional public-sector participation from Connecticut
Innovations. The Company is based in Farmington, CT, at the University
of Connecticut's Technology Incubation Program. For more information,
please visit

View Comments and Join the Discussion!